眼科治療の世界市場2020-2024

【英語タイトル】Global Ophthalmology Therapeutics Market 2020-2024

Technavioが出版した調査資料(TNV20FB074)・商品コード:TNV20FB074
・発行会社(調査会社):Technavio
・発行日:2020年1月31日
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「眼科治療の世界市場2020-2024」は、眼科治療について市場概要、市場規模、製品別(網膜障害治療薬、緑内障治療薬、ドライアイ疾患治療薬、眼感染症および炎症治療薬、その他の治療薬)分析、顧客状況、地域状況、市場の要因・課題、市場トレンド、企業状況、企業分析などを総合的にまとめて調査・分析したものです。
・エグゼクティブサマリー
・レポート範囲
・市場概要
・市場規模
・ファイブフォース分析
・眼科治療の世界市場:製品別(網膜障害治療薬、緑内障治療薬、ドライアイ疾患治療薬、眼感染症および炎症治療薬、その他の治療薬)
・顧客状況
・地域状況
・決定フレームワーク
・市場の要因・課題
・市場トレンド
・企業状況
・企業分析
【レポートの概要】

Global Ophthalmology Therapeutics Market 2020-2024
Technavio has been monitoring the global ophthalmology therapeutics market and it is poised to grow by USD 10.42 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period. Our reports on global ophthalmology therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in prevalence of eye diseases. In addition, development of novel drug delivery systems is anticipated to boost the growth of the global ophthalmology therapeutics market as well.

Market Segmentation

Technavio’s global ophthalmology therapeutics market is segmented as below:
Product
• Retinal Disorder Therapeutics
• Glaucoma Therapeutics
• Dry Eye Disease Therapeutics
• Eye Infections and Inflammation Therapeutics
• Other Therapeutics

Geographic segmentation
• North America
• Europe
• Asia
• ROW

Key Trends for global ophthalmology therapeutics market growth
This study identifies development of novel drug delivery systems as the prime reasons driving the global ophthalmology therapeutics market growth during the next few years.

Prominent vendors in global ophthalmology therapeutics market
We provide a detailed analysis of around 25 vendors operating in the global ophthalmology therapeutics market, including some of the vendors such as AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd.

The study was conducted using an objective combination of primary and secondary information including inputs from key icipants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit -https://www.technavio.com/report/global-ophthalmology-therapeutics-market-2020-2024

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

01: EXECUTIVE SUMMARY
02: SCOPE OF THE REPORT
1. 2.1 Preface
2. 2.2 Currency conversion rates for US$
03: MARKET LANDSCAPE
3. Market ecosystem
4. Parent market
5. Market characteristics
6. Value chain analysis
7. Market segmentation analysis
04: MARKET SIZING
8. Market definition
9. Market sizing 2019
10. Market size and forecast 2019-2024
11. Market outlook
05: FIVE FORCES ANALYSIS
12. Bargaining power of buyers
13. Bargaining power of suppliers
14. Threat of new entrants
15. Threat of substitutes
16. Threat of rivalry
17. Market condition
06: MARKET SEGMENTATION BY PRODUCT
18. Market segmentation by product
19. Comparison by product
20. Retinal disorder therapeutics – Market size and forecast 2019-2024
21. Glaucoma therapeutics – Market size and forecast 2019-2024
22. Dry eye disease therapeutics – Market size and forecast 2019-2024
23. Eye infections and inflammation therapeutics –
24. Market size and forecast 2019-2024
25. Other therapeutics – Market size and forecast 2019-2024
26. Market opportunity by product
07: CUSTOMER LANDSCAPE
08: GEOGRAPHIC LANDSCAPE
27. Geographic segmentation
28. Geographic comparison
29. North America – Market size and forecast 2019-2024
30. Europe – Market size and forecast 2019-2024
31. Asia – Market size and forecast 2019-2024
32. ROW – Market size and forecast 2019-2024
33. Key leading countries
34. Market opportunity
09: DECISION FRAMEWORK
10: DRIVERS AND CHALLENGES
35. Market drivers
36. Market challenges
11: MARKET TRENDS
37. Development of novel drug delivery systems
38. Increase in strategic alliances
39. Increasing research on gene therapy products
12: VENDOR LANDSCAPE
40. Overview
41. Landscape disruption
42. Competitive scenario
13: VENDOR ANALYSIS
43. Vendors covered
44. Vendor classification
45. Market positioning of vendors
46. AbbVie Inc.
47. Aerie Pharmaceuticals Inc.
48. Bayer AG
49. F. Hoffmann-La Roche Ltd.
50. Novartis AG
51. Otsuka Holdings Co. Ltd.
52. Pfizer Inc.
53. Regeneron Pharmaceuticals Inc.
54. Santen Pharmaceutical Co. Ltd.
55. Teva Pharmaceutical Industries Ltd.
14: APPENDIX
56. Research methodology
57. List of abbreviations
58. Definition of market positioning of vendors
15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Product – Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Retinal disorder therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Retinal disorder therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 22: Glaucoma therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Glaucoma therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 24: Dry eye disease therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Dry eye disease therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 26: Eye infections and inflammation therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 27: Eye infections and inflammation therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 28: Other therapeutics – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: Other therapeutics – Year-over-year growth 2020-2024 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2019-2024 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: North America – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in North America
Exhibit 37: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in Europe
Exhibit 40: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 41: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 42: Top 3 countries in Asia
Exhibit 43: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 44: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 45: Top 3 countries in ROW
Exhibit 46: Key leading countries
Exhibit 47: Market opportunity
Exhibit 48: Late-stage pipeline drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie Inc. – Vendor overview
Exhibit 56: AbbVie Inc. – Business segments
Exhibit 57: AbbVie Inc. – Organizational developments
Exhibit 58: AbbVie Inc. – Geographic focus
Exhibit 59: AbbVie Inc. – Key offerings
Exhibit 60: AbbVie Inc. – Key customers
Exhibit 61: Aerie Pharmaceuticals Inc. – Vendor overview
Exhibit 62: Aerie Pharmaceuticals Inc. – Business segments
Exhibit 63: Aerie Pharmaceuticals Inc. – Organizational developments
Exhibit 64: Aerie Pharmaceuticals Inc. – Key offerings
Exhibit 65: Aerie Pharmaceuticals Inc. – Key customers
Exhibit 66: Bayer AG – Vendor overview
Exhibit 67: Bayer AG – Business segments
Exhibit 68: Bayer AG – Organizational developments
Exhibit 69: Bayer AG – Geographic focus
Exhibit 70: Bayer AG – Segment focus
Exhibit 71: Bayer AG – Key offerings
Exhibit 72: Bayer AG – Key customers
Exhibit 73: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 74: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 75: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 76: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 77: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 78: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 79: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 80: Novartis AG – Vendor overview
Exhibit 81: Novartis AG – Business segments
Exhibit 82: Novartis AG – Organizational developments
Exhibit 83: Novartis AG – Geographic focus
Exhibit 84: Novartis AG – Segment focus
Exhibit 85: Novartis AG – Key offerings
Exhibit 86: Novartis AG – Key customers
Exhibit 87: Otsuka Holdings Co. Ltd. – Vendor overview
Exhibit 88: Otsuka Holdings Co. Ltd. – Business segments
Exhibit 89: Otsuka Holdings Co. Ltd. – Organizational developments
Exhibit 90: Otsuka Holdings Co. Ltd. – Geographic focus
Exhibit 91: Otsuka Holdings Co. Ltd. – Segment focus
Exhibit 92: Otsuka Holdings Co. Ltd. – Key offerings
Exhibit 93: Otsuka Holdings Co. Ltd. – Key customers
Exhibit 94: Pfizer Inc. – Vendor overview
Exhibit 95: Pfizer Inc. – Business segments
Exhibit 96: Pfizer Inc. – Organizational developments
Exhibit 97: Pfizer Inc. – Geographic focus
Exhibit 98: Pfizer Inc. – Segment focus
Exhibit 99: Pfizer Inc. – Key offerings
Exhibit 100: Pfizer Inc. – Key customers
Exhibit 101: Regeneron Pharmaceuticals Inc. – Vendor overview
Exhibit 102: Regeneron Pharmaceuticals Inc. – Business segments
Exhibit 103: Regeneron Pharmaceuticals Inc. – Organizational developments
Exhibit 104: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibit 105: Regeneron Pharmaceuticals Inc. – Key customers
Exhibit 106: Santen Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 107: Santen Pharmaceutical Co. Ltd. – Business segments
Exhibit 108: Santen Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 109: Santen Pharmaceutical Co. Ltd. – Segment focus
Exhibit 110: Santen Pharmaceutical Co. Ltd. – Key offerings
Exhibit 111: Santen Pharmaceutical Co. Ltd. – Key customers
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 115: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 116: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 117: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 118: Validation techniques employed for market sizing
Exhibit 119: Definition of market positioning of vendors




【掲載企業】

AbbVie Inc.
Aerie Pharmaceuticals Inc.
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Otsuka Holdings Co. Ltd.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.

★調査レポート[眼科治療の世界市場2020-2024] (コード:TNV20FB074)販売に関する免責事項を必ずご確認ください。
★調査レポート[眼科治療の世界市場2020-2024]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆